Adolescent With Down Syndrome Who Refuses to Walk

Bleyer A O’Leary M Barr R Ries LAG . Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. Bethesda, MD: National Cancer Institute; 2006.

Stiller CA Bielack SS Jundt G Steliarova-Foucher E . Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System Project. Eur J Cancer. 2006;42:2124-2135.

Gurney JG Swensen AR Bulterys M . Malignant bone tumors. In: Ries LAG Smith MA Gurney JG , et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute; 1999:99-110.

Jawad MU Cheung MC Min MS Schneiderbauer MM Koniaris LG Scully SP . Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer. 2009;115:3526-3536.

Zucman J Delattre O Desmaze C , et al. Cloning and characterization of the Ewing’s sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer. 1992;5:271-277.

Ohno T Ouchida M Lee L Gatalica Z Rao VN Reddy ES . The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene. 1994;9:3087-3097.

Zipursky A Peeters M Poon A . Megakaryoblastic leukemia and Down’s syndrome: a review. Pediatr Hematol Oncol. 1987;4:211-230.

Whitlock JA . Down syndrome and acute lymphoblastic leukaemia. Br J Haematol. 2006;135:595-602.

Goldacre MJ Wotton CJ Seagroatt V Yeates D . Cancers and immune related diseases associated with Down’s syndrome: a record linkage study. Arch Dis Child. 2004;89:1014-1017.

Antonarakis SE . Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet. 2017;18:147-163.

Hasle H Clemmensen IH Mikkelsen M . Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165-169.

Hasle H Friedman JM Olsen JH Rasmussen SA . Low risk of solid tumors in persons with Down syndrome. Genet Med. 2016;18:1151-1157.

Fuentes JJ Genescà L Kingsbury TJ , et al. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet. 2000;9:1681-1690.

Zorick TS Mustacchi Z Bando SY , et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet. 2001;9:811-814.

Bridge JA Neff JR Borek DA Hackbarth DA . Primary skeletal Ewing’s sarcoma in Down syndrome. Cancer Genet Cytogenet. 1990;47:61-68.

Casorzo L Fessia J Sapino A Ponzio G Bussolati G . Extraskeletal Ewing’s tumor with translocation t(11;22) in a patient with Down syndrome. Cancer Genet Cytogenet. 1989;37:79-84.

Glass AG Fraumeni JF Jr. Epidemiology of bone cancer in children. J Natl Cancer Inst. 1970;44:187-199.

Miller RW . Childhood cancer and congenital defects. A study of US death certificates during the period 1960-1966. Pediatr Res. 1969;3:389-397.